Skip to content
Subscriber Only

Senators Scrutinize Mylan Over EpiPen’s U.S. Price Increases

  • Grassley asks drugmaker to provide information on pricing
  • Klobuchar calls for FTC to look into business practices
Updated on

Two senior U.S. senators are examining Mylan NV’s price increases for the popular EpiPen allergy shot, with lawmakers saying the drugmaker’s practices may have limited competition and access to the treatment.

Senator Charles Grassley, an Iowa Republican, asked the drugmaker to explain “a steep price increase in the product in recent years,” citing complaints from constituents who say they have to pay as much as $500 for one prescription. Grassley heads the Senate Committee on the Judiciary.